We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
- Authors
Rini, Brian I; Halabi, Susan; Rosenberg, Jonathan E; Stadler, Walter M; Vaena, Daniel A; Archer, Laura; Atkins, James N; Picus, Joel; Czaykowski, Piotr; Dutcher, Janice; Small, Eric J
- Abstract
Bevacizumab is an antibody that binds vascular endothelial growth factor and has activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN-alpha) is the historic standard initial treatment for RCC. A prospective, randomized, phase III trial of bevacizumab plus IFN-alpha versus IFN-alpha monotherapy was conducted.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Vol 28, Issue 13, p2137
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2009.26.5561